Third Rock-backed Cedil­la reels in $57.6M for small mol­e­cule pro­grams to fight can­cer

Cedil­la Ther­a­peu­tics launched just over two years ago with a $56 mil­lion Se­ries A and a plan to chart new ter­ri­to­ry in the pro­tein degra­da­tion space. Now, CEO San­dra Glucks­mann is fol­low­ing up with a $57.6 mil­lion Se­ries B round to steer the Cam­bridge, MA-based biotech in a slight­ly dif­fer­ent di­rec­tion.

The com­pa­ny is cur­rent­ly fo­cused on find­ing new small mol­e­cule bind­ing sites — which may af­fect pro­tein degra­da­tion, in­hi­bi­tion or both — to drug the un­drug­gable.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER